

RESIST-TB

Research Excellence to Stop TB Resistance

RESIST-TB ANNUAL REPORT FOR 2025

RESIST-TB is an organization of concerned patients, physicians, research scientists and stakeholders. Its mission is to facilitate and promote clinical research to cure and prevent drug-resistant tuberculosis (DR-TB). RESIST-TB is committed to addressing the substantial existing gaps in knowledge and to helping provide access to effective curative and preventive treatment for DR-TB. Efforts have been supported by the Stop TB Partnership, the International Union Against Tuberculosis and Lung Disease, Treatment Action Group, Partners In Health, the U. S. Centers for Disease Control & Prevention, Vital Strategies and Médecins Sans Frontières.

Our 2025 activities centered on:

(1) DR-TB scientific advocacy through dissemination of information through our website, including promoting and arranging a series of webinars and an eNewsletter, publicizing weekly news articles, organizing a symposium at the International Union Against Tuberculosis and Lung Disease's annual World Conference on Lung Health (Copenhagen) and contributing to published literature on DR-TB testing and treatment.

And

(2) Driving public policy change by producing data demonstrating gaps in care for DR-TB globally and disseminating new developments and best practices in DR-TB treatment.

Details are provided below.

SCIENTIFIC ADVOCACY

RESIST-TB WEBSITE AND eNEWSLETTER

The RESIST-TB website (www.resisttb.org) remains active to share advances in DR-TB clinical trials and disseminate news, developments, and publications. Our website is updated weekly and our newsletter is distributed to 535 subscribers. In our monthly eNewsletter, we highlight information about new DR-TB-treatment related publications, provide news updates, and inform readers about upcoming events. Featured news articles covered DR-TB clinical trial results, developments in the use of drugs and susceptibility testing, publication announcements, symposia, advocacy initiatives, and webinars of interest in addition to global headlines related to DR-TB.

CLINICAL TRIALS PROGRESS REPORT

RESIST-TB continues to be a critical source for up-to-date information on clinical trials for DR-TB. The Clinical Trials Progress Report gathers and maintains updated information on DR-TB clinical trials that are underway and/or in development, including study names, description, status, study enrollment size, and links to more information. We currently track 36 clinical

RESIST-TB

Research Excellence to Stop TB Resistance

trials: 8% are Phase 1, 47% are Phase 2, 33% are Phase 3, and 8% are Phase 4; 25% are currently enrolling participants, and 8% have completed enrollment and follow up, or data analysis is ongoing, and 61% have been completed with results. This resource is updated on a monthly basis with downloadable versions available in PDF and Microsoft Powerpoint. The [Clinical Trials Progress Report](#) page is the most visited page on RESIST-TB's website, aside from the homepage.

2025 also saw the completion of the 2024-25 RESIST-TB survey on international availability of drug susceptibility testing. In November 2024, RESIST-TB surveyed members of the TB Section of the International Union Against Tuberculosis and Lung Disease and the Global Laboratory Initiative of the World Health Organization using a 14-question quantitative and qualitative survey in order to update information on international availability of drug susceptibility testing and compare results to the 2019 survey and publication titled [Global availability of susceptibility testing for second-line anti-tuberculosis agents](#). The 2025 report summarizes the findings from the 25 responses received and is available on the [RESIST-TB website](#).

In summary, the 2024 survey served to determine if progress had been made on the international availability of antibiotic susceptibility testing to second line drugs since the previous survey in 2019. Responses for each question were assessed and/or reported as proportions (out of the total completed responses). The survey only received 25 responses, although all WHO regions were represented. Most respondents reported having capacity for DST for fluoroquinolones and second-line injectables. Compared to 2019, there was increased availability of testing from bedaquiline, clofazimine, delamanid, and linezolid, with no significant change for fluoroquinolones and a modest decrease for injectables. The greatest proportion of respondents reported sending samples for 1st line DST more than 10km and sending samples for 2nd line DST more than 50km. Finally, the greatest proportion of respondents shared an average turnaround time from sample collection to results for both 1st line DST and 2nd line DST greater than 21 days, respectively. These results show that availability of susceptibility testing for the new agents increased, although not all areas were yet served.

INCREASING AWARENESS TO CHANGE PUBLIC POLICY

WEBINAR SERIES

Since 2015, RESIST-TB has hosted a webinar series on recent developments in DR-TB. This webinar series serves as a forum for updates on pressing issues in the field of MDR-TB through presentations on recent publications. The webinar series also helps fill a critical and otherwise unmet gap in disseminating new, unpublished advances in MDR-TB care and treatment. Webinars hosted as part of this series during 2025 are listed below. Slides and on-demand recordings can be found [here](#):

- **Hear about endTB-Q Results**, Presentation by Dr. Carole Mitnick on January 16th, 2025

RESIST-TB

Research Excellence to Stop TB Resistance

Description: This webinar included a presentation on the preliminary results of endTB-Q.

- **Hear about BEAT-TB Results**, Presentation by Dr. Francesca Conradie on April 17th, 2025

Description: This webinar included a presentation on the results of BEAT-TB South Africa.

- **Hear about updates from the PAN-TB trial**, Presentation by Dr. David Holtzman on May 22nd, 2025

Description: This webinar included a presentation on recent and significant updates from the PAN-TB trial.

- **Everything is Tuberculosis with John Green**, Discussion with John Green on September 11th, 2025.

Description: This webinar shared insight and prompted a discussion on the NYT best-selling book *Everything is Tuberculosis: The History and Persistence of Our Deadliest Infection*.

- **Long-Acting Injectables for TB Treatment** Presentations by Erin McConnell, Charles Wells and Eric Nuermberger on October 2nd, 2025.

Description: Presenters shared research and findings on long-acting injectables and their potential for preventing and/or treating TB.

RESIST-TB GOALS FOR 2025 AND BEYOND

RESIST-TB began another survey in December 2025 among members of the TB Section of the International Union Against Tuberculosis and Lung Disease and the Global Laboratory Initiative of the World Health Organization to update information on the current practice and management of isoniazid-resistant TB in various settings. If you have not already responded to the survey, we want to hear from you. Please follow the link [here](#).

RESIST-TB

Research Excellence to Stop TB Resistance

LEADERSHIP CHANGE

In 2025, Founding Steering Committee Chair Dr. C. Robert Horsburgh announced his intention to step down from day-to-day management of RESIST-TB activities in June 2025. We thank Bob for his tireless service to the RESIST-TB community and seek a new generation of leaders to continue this work. If you are interested in participating, please email resisttb@gmail.com.

CONCLUSION

RESIST-TB fills an important unmet need for innovation, information dissemination and advocacy. By addressing research and implementation gaps in the treatment and prevention of MDR-TB, we draw attention to areas still in need of research. We also undertake important research projects that are not currently being addressed by the global TB community. Our focus remains the development and demonstration of efficacy of scalable, nontoxic regimens for the treatment of DR-TB and facilitation of rapid translation of these advances into practice. The successful continuation of these activities is critical to continued improvement in treatment and prevention of MDR-TB and XDR-TB.